146 related articles for article (PubMed ID: 36551548)
1. Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma.
Gulati R; Hanlon MA; Lutz M; Quitmeyer T; Geller J; Tiao G; Timchenko L; Timchenko N
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551548
[TBL] [Abstract][Full Text] [Related]
2. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
[TBL] [Abstract][Full Text] [Related]
3. Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.
Johnston ME; Rivas MP; Nicolle D; Gorse A; Gulati R; Kumbaji M; Weirauch MT; Bondoc A; Cairo S; Geller J; Tiao G; Timchenko N
Hepatology; 2021 Oct; 74(4):2201-2215. PubMed ID: 34037269
[TBL] [Abstract][Full Text] [Related]
4. Cellular origin and molecular mechanisms of lung metastases in patients with aggressive hepatoblastoma.
Gulati R; Lutz M; Hanlon M; Cast A; Karns R; Geller J; Bondoc A; Tiao G; Timchenko L; Timchenko NA
Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285876
[TBL] [Abstract][Full Text] [Related]
5. PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.
Valanejad L; Cast A; Wright M; Bissig KD; Karns R; Weirauch MT; Timchenko N
Commun Biol; 2018; 1():67. PubMed ID: 30271949
[TBL] [Abstract][Full Text] [Related]
6. Molecular signatures of aggressive pediatric liver cancer.
Johnston ME; Timchenko N
Arch Stem Cell Ther; 2021; 2(1):1-4. PubMed ID: 34447970
[TBL] [Abstract][Full Text] [Related]
7. HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer.
Rivas M; Johnston ME; Gulati R; Kumbaji M; Margues Aguiar TF; Timchenko L; Krepischi A; Shin S; Bondoc A; Tiao G; Geller J; Timchenko N
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1669-1682. PubMed ID: 34245919
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA therapy inhibits hepatoblastoma growth
Indersie E; Lesjean S; Hooks KB; Sagliocco F; Ernault T; Cairo S; Merched-Sauvage M; Rullier A; Le Bail B; Taque S; Grotzer M; Branchereau S; Guettier C; Fabre M; Brugières L; Hagedorn M; Buendia MA; Grosset CF
Hepatol Commun; 2017 Apr; 1(2):168-183. PubMed ID: 29404451
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor Egr1 acts as an upstream regulator of beta-catenin signalling through up-regulation of TCF4 and p300 expression during trans-differentiation of endometrial carcinoma cells.
Saegusa M; Hashimura M; Kuwata T; Hamano M; Watanabe J; Kawaguchi M; Okayasu I
J Pathol; 2008 Dec; 216(4):521-32. PubMed ID: 18798221
[TBL] [Abstract][Full Text] [Related]
10. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
Yamaoka H; Ohtsu K; Sueda T; Yokoyama T; Hiyama E
Oncol Rep; 2006 Mar; 15(3):551-6. PubMed ID: 16465411
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
13. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
Zhou S; Parham DM; Yung E; Pattengale P; Wang L
Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
[TBL] [Abstract][Full Text] [Related]
14. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
[TBL] [Abstract][Full Text] [Related]
15. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?
Ceballos MP; Parody JP; Alvarez Mde L; Ingaramo PI; Carnovale CE; Carrillo MC
Biochem Pharmacol; 2011 Dec; 82(11):1682-91. PubMed ID: 21843516
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of TCF4 expression as a transcriptional target of beta-catenin/p300 complexes during trans-differentiation of endometrial carcinoma cells.
Saegusa M; Hashimura M; Kuwata T; Hamano M; Okayasu I
Lab Invest; 2005 Jun; 85(6):768-79. PubMed ID: 15806138
[TBL] [Abstract][Full Text] [Related]
17. C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer.
Cast A; Valanejad L; Wright M; Nguyen P; Gupta A; Zhu L; Shin S; Timchenko N
Hepatology; 2018 May; 67(5):1857-1871. PubMed ID: 29159818
[TBL] [Abstract][Full Text] [Related]
18. The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/β-catenin coactivators essential for intestinal homeostasis.
Mahmoudi T; Boj SF; Hatzis P; Li VS; Taouatas N; Vries RG; Teunissen H; Begthel H; Korving J; Mohammed S; Heck AJ; Clevers H
PLoS Biol; 2010 Nov; 8(11):e1000539. PubMed ID: 21103407
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
[TBL] [Abstract][Full Text] [Related]
20. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
